HPS-142 - Pembrolizumab related Early-Onset Pancytopenia: A case report and literature review

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: HPS-142
• By: HSU, Wei Cheng (Department of Pharmacy, Cathay General Hospital, China Taiwan)
• Co-author(s): Ms Wei Cheng Hsu (Department of Pharmacy, Cathay General Hospital, Taipei, China Taiwan / Taipei Pharmacists Association, Taipei, China Taiwan)
  Mrs Chi-Lan Kao (Department of Pharmacy, Cathay General Hospital, Taipei, China Taiwan / Taipei Pharmacists Association, Taipei, China Taiwan)
  
• Abstract:

  Background
  Pembrolizumab, a PD-1 inhibitor, is approved for treating metastatic melanoma and other malignancies. While immune checkpoint inhibitors (ICIs) are known to cause immune-related adverse events (irAEs), hematologic toxicities such as pancytopenia remain rare. This report presents a suspected case of Pembrolizumab-induced pancytopenia,..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login